Polaryx Therapeutics Management
Management criteria checks 2/4
Polaryx Therapeutics' CEO is Alex Yang, appointed in Mar 2023, has a tenure of 3.33 years. directly owns 1.93% of the company’s shares, worth $2.12M. The average tenure of the management team and the board of directors is 2.3 years and 0.5 years respectively.
Key information
Alex Yang
Chief executive officer
US$792.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.3yrs |
| CEO ownership | 1.9% |
| Management average tenure | 2.3yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Alex Yang (56 yo)
Mr. Alex Yang, J.D., L.L.M., is CEO of Board of Polaryx Therapeutics, Inc. from March 2023 and has been its Chair of the board since June 2021. In 2016, Mr. Yang founded Mstone, a biotech incubation and in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chair of Board | 3.3yrs | US$792.00k | 1.93% $ 2.1m | |
| CFO & Director | 2.1yrs | US$310.67k | 0.061% $ 66.9k | |
| Chief Investment Officer | 4.5yrs | US$308.00k | 0.32% $ 355.2k | |
| Chief Medical Officer | less than a year | US$712.19k | 0.00076% $ 838.4 | |
| Chief Scientific & Business Development Officer | 2.4yrs | no data | no data | |
| Chief Chemistry | 1.4yrs | no data | no data |
Experienced Management: PLYX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chair of Board | 5.1yrs | US$792.00k | 1.93% $ 2.1m | |
| CFO & Director | less than a year | US$310.67k | 0.061% $ 66.9k | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data |
Experienced Board: PLYX's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 22:48 |
| End of Day Share Price | 2026/07/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Polaryx Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |